Lantinga, Marten A.
D’Agnolo, Hedwig M. A.
Casteleijn, Niek F.
de Fijter, Johan W.
Meijer, Esther
Messchendorp, Annemarie L.
Peters, Dorien J. M.
Salih, Mahdi
Spithoven, Edwin M.
Soonawala, Darius
Visser, Folkert W.
Wetzels, Jack F. M.
Zietse, Robert
Drenth, Joost P. H.
Gansevoort, Ron T.
,
Drenth, J. P. H.
de Fijter, J. W.
Gansevoort, R. T.
Peters, D. J. M.
Wetzels, J.
Zietse, R.
Funding for this research was provided by:
Nierstichting (CP10.12)
Ipsen Farmaceutica B.V.
Article History
First Online: 19 December 2016
Compliance with Ethical Standards
:
: The DIPAK-1 study is made possible by a grant from the Dutch Kidney Foundation (CP10.12), with Ipsen Farmaceutica B.V., the Netherlands acting as a minor co-sponsor. The Dutch Kidney Foundation and Ipsen had no role in the design or conduct of the study, or in the writing and submission of the manuscript.
: Marten A. Lantinga, Hedwig M.A. D’Agnolo, Niek F. Casteleijn, Johan W. de Fijter, Esther Meijer, Annemarie L. Messchendorp, Dorien J.M. Peters, Mahdi Salih, Darius Soonawala, Folkert W. Visser, and Jack F.M. Wetzels have no conflicts of interest that are directly relevant to the content of this study. Edwin M. Spithoven has received payment for an Otsuka presentation about the epidemiology of ADPKD and future perspectives. Robert Zietse has received previous grant support from Ipsen. Joost P.H. Drenth has received previous grant support from Ipsen and Novartis. Ron T. Gansevoort holds the rights on the Orphan Designation status of lanreotide for the indication ADPKD, which was granted by the European Medicines Agency (EU/3/15/1514).
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.